Terms: = Gastric cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
637 results:
1. gastric cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.
Shen J; Li M
Crit Rev Immunol; 2024; 44(5):1-13. PubMed ID: 38618724
[TBL] [Abstract] [Full Text] [Related]
2.
Kalisperati P; Spanou E; Pateras IS; Evangelou K; Thymara I; Korkolopoulou P; Kotsinas A; Vlachoyiannopoulos PG; Tzioufas AG; Kanellopoulos C; Gorgoulis VG; Sougioultzis S
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612698
[No Abstract] [Full Text] [Related]
3. [Pyloric gland adenoma - a rare tumor of the upper gastrointestinal tract with a high risk of malignancy].
Tertychnyy AS; Pachuashvili NV; Protsenko DD; Avraamova ST; Nagornaya DP; Pavlov PV; Kiryukhin AP; Fedorenko AA
Arkh Patol; 2024; 86(2):30-36. PubMed ID: 38591904
[TBL] [Abstract] [Full Text] [Related]
4. Valproate modulates the activity of multidrug resistance efflux pumps, as a chemoresistance factor in gastric cancer cells.
Hosseini SA; Mirzaei SA; Kermani S; Yaghoobi H
Mol Biol Rep; 2024 Mar; 51(1):427. PubMed ID: 38498238
[TBL] [Abstract] [Full Text] [Related]
5. Differential genetic mutations and immune cell infiltration in high- and low-risk STAD: Implications for prognosis and immunotherapy efficacy.
Deng YY; Sun Y; Wu SJ; Zhang TY; Yang J; Liu K
J Cell Mol Med; 2024 Apr; 28(7):e18174. PubMed ID: 38494839
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Classifications in gastric cancer: A Call for Interdisciplinary Collaboration.
Díaz Del Arco C; Fernández Aceñero MJ; Ortega Medina L
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473896
[TBL] [Abstract] [Full Text] [Related]
7. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.
Yang T; Gou H; Lin T; Yang Y; Jin X; Dong T; Zhang Y; Chen X
Int J Pharm; 2024 Apr; 654():123971. PubMed ID: 38452832
[TBL] [Abstract] [Full Text] [Related]
8. The role of mir96 in predicting CTC status and prognostic evaluation in gastric cancer patients.
Zheng Q; Ge H
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):264-274. PubMed ID: 38430012
[TBL] [Abstract] [Full Text] [Related]
9. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming.
Zou G; Huang Y; Zhang S; Ko KP; Kim B; Zhang J; Venkatesan V; Pizzi MP; Fan Y; Jun S; Niu N; Wang H; Song S; Ajani JA; Park JI
J Exp Med; 2024 Apr; 221(4):. PubMed ID: 38411616
[TBL] [Abstract] [Full Text] [Related]
10. Killer cell lectin-like receptor G2 facilitates aggressive phenotypes of gastric cancer cells via dual activation of the ERK1/2 and JAK/STAT pathways.
Ito Y; Kanda M; Sasahara M; Tanaka C; Shimizu D; Umeda S; Inokawa Y; Hattori N; Hayashi M; Nakayama G; Kodera Y
Gastric Cancer; 2024 May; 27(3):506-518. PubMed ID: 38386237
[TBL] [Abstract] [Full Text] [Related]
11. treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetic disruption of histone deacetylase-2 accelerated apoptotic signaling and retarded malignancy in gastric cells.
Hosseini SA; Ghatrehsamani M; Yaghoobi H; Elahian F; Mirzaei SA
Epigenomics; 2024 Mar; 16(5):277-292. PubMed ID: 38356395
[TBL] [Abstract] [Full Text] [Related]
13. The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.
Riegel G; Orvain C; Recberlik S; Spaety ME; Poschet G; Venkatasamy A; Yamamoto M; Nomura S; Tsukamoto T; Masson M; Gross I; Le Lagadec R; Mellitzer G; Gaiddon C
Cancer Lett; 2024 Mar; 585():216671. PubMed ID: 38290658
[TBL] [Abstract] [Full Text] [Related]
14. Tissue Organoid Cultures Metabolize Dietary Carcinogens Proficiently and Are Effective Models for DNA Adduct Formation.
Caipa Garcia AL; Kucab JE; Al-Serori H; Beck RSS; Bellamri M; Turesky RJ; Groopman JD; Francies HE; Garnett MJ; Huch M; Drost J; Zilbauer M; Arlt VM; Phillips DH
Chem Res Toxicol; 2024 Feb; 37(2):234-247. PubMed ID: 38232180
[TBL] [Abstract] [Full Text] [Related]
15. Global burden, risk factors, clinicopathological characteristics, molecular biomarkers and outcomes of microsatellite instability-high gastric cancer.
Zhang Z; Huang J; Li Y; Yan H; Xie J; Wang J; Zhao B
Aging (Albany NY); 2024 Jan; 16(1):948-963. PubMed ID: 38224334
[TBL] [Abstract] [Full Text] [Related]
16. [Clinicopathological features of gastric alpha-fetoprotein-producing adenocarcinoma with SWI/SNF complex deletion].
Yang JZ; Guo XX; Xu C; Hou YY; Yuan W
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):52-57. PubMed ID: 38178747
[No Abstract] [Full Text] [Related]
17. Medicine for chronic atrophic gastritis: a systematic review, meta- and network pharmacology analysis.
Weng J; Wu XF; Shao P; Liu XP; Wang CX
Ann Med; 2023; 55(2):2299352. PubMed ID: 38170849
[TBL] [Abstract] [Full Text] [Related]
18. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
19. An emerging biomarker for the diagnosis and treatment of esophageal squamous cell carcinoma - Aurora A.
Zhou W; Guo S; Zhang J; Yan Y; Wu J; Liu X
Comput Biol Med; 2024 Jan; 168():107759. PubMed ID: 38043467
[TBL] [Abstract] [Full Text] [Related]
20. Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.
Geng H; Qian R; Zhong Y; Tang X; Zhang X; Zhang L; Yang C; Li T; Dong Z; Wang C; Zhang Z; Zhu C
Cancer Gene Ther; 2024 Feb; 31(2):334-348. PubMed ID: 38040871
[TBL] [Abstract] [Full Text] [Related]
[Next]
